Follow us:

科研产品

  • 基因表达PCR芯片
  • 体细胞突变PCR芯片
  • 拷贝数变化PCR芯片
  • 基因分型PCR芯片
  • 蛋白表达抗体芯片
  • 蛋白磷酸化抗体芯片
  • 蛋白质相互作用芯片
  • 引物和探针
  • 常规分子生物学试剂

  • 临床产品

  • 个性化用药
  • 易感基因检测
  • 生物标志物试剂盒

  • > 产品目录 > 科研产品 > 体细胞突变PCR芯片 > c-MET通路突变PCR芯片

    c-MET,又被称为MET或HGFR,作为一种膜受体,在胚胎发育和伤口愈合方面发挥重要作用。肝细胞生长因子(HGF)是目前唯一已知的c-MET受体。C-MET功能异常与多种恶性肿瘤相关,如肾癌,肝癌,胃癌,乳腺癌以及脑肿瘤等。肿瘤中c-MET的异常激活可促进肿瘤生长,血管生成及转移,提示肿瘤较差的预后。c-MET激活可促进下游Ras-MAPK, PI3K, STAT, beta-catenin以及 Notch的活化,促进肿瘤发生。

    c-MET,又被称为MET或HGFR,作为一种膜受体,在胚胎发育和伤口愈合方面发挥重要作用。肝细胞生长因子(HGF)是目前唯一已知的c-MET受体。C-MET功能异常与多种恶性肿瘤相关,如肾癌,肝癌,胃癌,乳腺癌以及脑肿瘤等。肿瘤中c-MET的异常激活可促进肿瘤生长,血管生成及转移,提示肿瘤较差的预后。c-MET激活可促进下游Ras-MAPK, PI3K, STAT, beta-catenin以及 Notch的活化,促进肿瘤发生。
     
    人c-MET通路体细胞突变PCR芯片可适用于快速、准确的检测c-MET基因及其下游Ras-MAPK和PI3K两个主要通路的关键基因检测。利用单个或多个体细胞突变信息检测关键信号通路异常已被广泛应用于临床研究。例如: EGFR和KRAS基因突变能够预测靶向该位点的药物治疗响应。c-MET通路体细胞突变PCR芯片覆盖广泛,适用于c-MET通路及其下游基因的突变检测,并有望为临床相关疾病提供潜在药物治疗靶点。该芯片包含c-MET通路中83个最常见并具有重要功能和生理学意义的突变位点。突变位点主要由多种体细胞突变数据库以及经同行评阅的科学文献筛选得到。芯片操作简单,只需借助real-time PCR仪即可完成,应用广泛。
     
    体细胞突变PCR芯片仅适用于分子生物学研究,不适用疾病的临床诊断及治疗。

     
    Assay functional annotations
    c-MET gene:
    The assays included in this panel detect the most frequently identified c-MET gain-of-function mutations, such as the
    tyrosine kinase domain and juxtamembrane domain point mutations.
    AKT gene:
    The mutation assay detects the best known AKT1 mutation, c.49G>A, p.E17K. This is a PH domain mutation that
    results in constitutive targeting of AKT1 to plasma membrane.
    BRAF gene:
    Two classes of mutation assays are included. One class covers mutations that lead to increased BRAF kinase activity, such as the p.V600 mutations. The other class detects mutations that lead to impaired kinase activity, such as the p.G469A mutation.
    KRAS gene:
    12 KRAS mutation assays provide comprehensive analysis capacity for the most frequently occurring mutations in KRAS codon positions 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP.
    HRAS gene:
    Similar to KRAS mutation assays, the 8 HRAS mutation assays on this panel aim to cover the most important HRAS mutations identified in cancers at codon 12, 13, and 61 positions.
    NRAS gene:
    10 NRAS mutation assays are included on the panel to cover codon positions 12, 13, and 61.
    MEK1 gene:
    4 assays for mutations with significance in cancer were included on this panel. These mutations cluster in MEK1 Nterminal negative regulatory domain and an adjacent domain, and are all activating mutations (i.e. lead to upregulated intrinsic MEK1 kinase activity).
    PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) gene:
    The mutation assays covered on this panel can detect 6 of the most frequently occurring PIK3CA mutations that belong to two classes: p.H1047 mutations, which are activating, kinase domain mutations; and mutations in P539-E545 region, which are helical domain mutations that mimic activation by growth factors.
    PTEN gene:
    Included on the panel are 6 most commonly detected PTEN loss-of-function mutations that are due to either truncation (p.R233* and p.R130*) or point mutation-caused phosphatase inactivation (p.R130 and p.R173 mutations).
    PTPN11 gene:
    The 15 assays included in this panel detect the most frequently identified PTPN11 mutations, such as lesions affecting residues located in or close to the N-terminal SH2 domain/PTP-interacting surface, and mutations that affect residues that control substrate specificity.
    VHL gene:
    Included on the panel are 6 most commonly detected VHL point mutations or truncation mutations that lead to loss of tumor suppressor function of the VHL protein.

    规格:83个位点/array   1sample/array
    检测灵敏度:可以检测低至0.1%的体细胞突变


    更多了解产品和解决方案>>
    美好杏园你我共创